[go: up one dir, main page]

WO2004007557A3 - Tf antagonist - Google Patents

Tf antagonist Download PDF

Info

Publication number
WO2004007557A3
WO2004007557A3 PCT/DK2003/000480 DK0300480W WO2004007557A3 WO 2004007557 A3 WO2004007557 A3 WO 2004007557A3 DK 0300480 W DK0300480 W DK 0300480W WO 2004007557 A3 WO2004007557 A3 WO 2004007557A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
conjugates
relates
patho
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000480
Other languages
French (fr)
Other versions
WO2004007557A2 (en
Inventor
Henning Ralf Stennicke
Lars Christian Petersen
Soeren E Bjoern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to AU2003242506A priority Critical patent/AU2003242506A1/en
Publication of WO2004007557A2 publication Critical patent/WO2004007557A2/en
Publication of WO2004007557A3 publication Critical patent/WO2004007557A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to conjugates of tissue factor (TF) antagonists and a domain that act to elicit a cytotoxic response. The conjugate bind TF with high affinity and specificity but do not initiate blood coagulation. In one embodiment of the present invention the TF antagonist is FVIIa polypeptides chemically inactivated in the active site. In another embodiment the TF antagonist is an antibody against TF. The invention also relates to pharmaceutical compositions comprising the conjugates as well as their use in the prophylaxis or treatment of diseases or disorders related to patho-physiological TF functions including cancer, inflammation, atherosclerosis and ischemia/reperfusion.
PCT/DK2003/000480 2002-07-12 2003-07-09 Tf antagonist Ceased WO2004007557A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003242506A AU2003242506A1 (en) 2002-07-12 2003-07-09 Tf antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201100 2002-07-12
DKPA200201100 2002-07-12

Publications (2)

Publication Number Publication Date
WO2004007557A2 WO2004007557A2 (en) 2004-01-22
WO2004007557A3 true WO2004007557A3 (en) 2004-04-22

Family

ID=30011020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000480 Ceased WO2004007557A2 (en) 2002-07-12 2003-07-09 Tf antagonist

Country Status (2)

Country Link
AU (1) AU2003242506A1 (en)
WO (1) WO2004007557A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
GB2419774A (en) 2004-10-27 2006-05-03 Ericsson Telefon Ab L M Accessing IP multimedia subsystem (IMS) services
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
SMT201700547T1 (en) * 2010-06-15 2018-01-11 Genmab As Human antibody drug conjugates against tissue factor
DK3071237T3 (en) * 2013-11-21 2024-09-09 Genmab As LYOPHILIZED FORMULATION OF ANTIBODY DRUG CONJUGATE
US20190015532A1 (en) 2016-01-15 2019-01-17 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
US20190358351A1 (en) * 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii
UA130009C2 (en) 2018-05-07 2025-10-15 Генмаб А/С Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012800A1 (en) * 1994-10-24 1996-05-02 Zymogenetics, Inc. Modified factor vii
WO2000042973A2 (en) * 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001021661A1 (en) * 1999-09-20 2001-03-29 Novo Nordisk A/S BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX
JP2001213804A (en) * 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd Antitissue factor antibody complex

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012800A1 (en) * 1994-10-24 1996-05-02 Zymogenetics, Inc. Modified factor vii
WO2000042973A2 (en) * 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
WO2001002439A1 (en) * 1999-07-01 2001-01-11 Yale University Neovascular-targeted immunoconjugates
WO2001021661A1 (en) * 1999-09-20 2001-03-29 Novo Nordisk A/S BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX
JP2001213804A (en) * 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd Antitissue factor antibody complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200173, Derwent World Patents Index; Class B04, AN 2001-629603, XP002262305 *
H. MICHAEL ELLERBY ET AL: "Anti-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP002262304 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12246025B2 (en) 2018-03-21 2025-03-11 Genmab A/S Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US12453781B2 (en) 2018-10-30 2025-10-28 Genmab A/S Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

Also Published As

Publication number Publication date
AU2003242506A1 (en) 2004-02-02
WO2004007557A2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2004007557A3 (en) Tf antagonist
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
EP1423107A4 (en) CONJUGATES OF PHARMACEUTICAL AGENTS AND FATTY ALCOHOLS
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
EE200200578A (en) Therapeutic combinations of antihypertensive and anti-angiogenic agents
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
DE60223254D1 (en) DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
WO2005032470A3 (en) Compositions and methods for treating burns
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
DE69932510D1 (en) VASKULARISIERUNGSINHIBITOREN
BR0109515A (en) Apomorphine Derivatives and Methods for Their Use
WO2005042027A3 (en) Antagonists of the bradykinin b1 receptor
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
BR0313239A (en) Compound, pharmaceutical composition, and methods of treating or preventing pain and inflammation and disease
MXPA05011858A (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use.
BR0211604A (en) Integrin inhibitors for the treatment of eye disease
BRPI0412919A (en) combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders
WO2001076638A3 (en) Compositions for drug delivery
EA200100799A1 (en) ANTAGONISTS OF THE TUMOR NECROSE FACTOR AND THEIR APPLICATION IN ENDOMETRIOSIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP